文献速递糖尿病

代谢惰性胰岛素类似物不能预防NOD小鼠的自身免疫性糖尿病

Metabolically inactive insulin analogue does not prevent autoimmune diabetes in NOD mice.
PubMed 文献 · Diabetologia · 2017-04-28

该研究在三个地理区域的菌群环境中,对7-12周龄雌性NOD小鼠通过静脉或皮下多次注射代谢惰性胰岛素类似物(MII),评估其预防自身免疫性糖尿病的潜力。结果显示,每周两次皮下注射MII加速而非预防糖尿病;高剂量静脉治疗未预防疾病或影响胰岛素自身抗体水平,但增加了外周淋巴组织中胰岛素反应性CD4+ T淋巴细胞数量。结论提示MII即使高剂量也几乎无治疗潜力,并可能加重疾病。

要点

  • 每周两次皮下注射MII加速而非预防NOD小鼠糖尿病。
  • 高剂量静脉MII未预防疾病,未影响胰岛素自身抗体水平。
  • 高剂量静脉MII增加外周淋巴组织胰岛素反应性CD4+ T淋巴细胞。

核心结论

  • 研究数据提示,肠外给予MII即使高剂量在NOD小鼠中几乎无治疗潜力,并可能加重疾病。

研究设计与样本

  • 在三个地理区域菌群环境中,对7-12周龄非糖尿病雌性NOD小鼠通过静脉或皮下多次注射MII,观察糖尿病发病率、胰岛素自身抗体水平及胰岛素反应性T淋巴细胞数量。

主要发现

  • 每周两次皮下注射MII加速而非预防糖尿病。
  • 高剂量静脉治疗未预防疾病或影响胰岛素自身抗体水平,但增加外周淋巴组织中胰岛素反应性CD4+ T淋巴细胞数量。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Insulin is widely considered to be a driver antigen in type 1 diabetes in humans and in mouse models of the disease. Therefore, insulin or insulin analogues are candidates for tolerogenic drugs to prevent disease onset in individuals with risk of diabetes. Previous experiments have shown that autoimmune diabetes can be prevented in NOD mice by repeated doses of insulin administered via an oral, nasal or parenteral route, but clinical trials in humans have not succeeded. The hypoglycaemic activity of insulin is dose-limiting in clinical studies attempting tolerance and disease prevention. Here, we aimed to investigate the therapeutic potential of metabolically inactive insulin analogue (MII) in NOD mice. METHODS: The tolerogenic potential of MII to prevent autoimmune diabetes was studied by administering multiple i.v. or s.c. injections of MII to non-diabetic 7-12-week-old female NOD mice in three geographical colony locations. The incidence of diabetes was assessed from daily or weekly blood glucose measurements. The effect of MII on insulin autoantibody levels was studied using an electrochemiluminescence-based insulin autoantibody assay. The effect on the number of insulin-reactive CD8+ and CD4+ T lymphocytes in peripheral lymphoid tissue was studied with MHC class I and MHC class II tetramers, respectively. RESULTS: We found that twice-weekly s.c. administration of MII accelerates rather than prevents diabetes. High-dose i.v. treatment did not prevent disease or affect insulin autoantibody levels, but it increased the amount of insulin-reactive CD4+ T lymphocytes in peripheral lymphoid tissue. CONCLUSIONS/INTERPRETATION: Our data suggest that parenteral MII, even when used in high doses, has little or no therapeutic potential in NOD mice and may exacerbate disease.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Grönholm J, Pagni PP, Pham MN, et al. Metabolically inactive insulin analogue does not prevent autoimmune diabetes in NOD mice. Diabetologia. 2017. PMID: 28455654. doi:10.1007/s00125-017-4276-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。